Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, GuimarĂ£es CRW, Liu S, Niosi M, Skoura A, Tess D.

J Med Chem. 2018 Apr 12;61(7):3114-3125. doi: 10.1021/acs.jmedchem.8b00152. Epub 2018 Apr 3.

PMID:
29570292
2.

Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.

El-Kattan AF, Varma MVS.

Drug Metab Dispos. 2018 May;46(5):729-739. doi: 10.1124/dmd.117.080044. Epub 2018 Mar 1. Review.

PMID:
29496721
3.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.

Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):346-356. doi: 10.1124/dmd.117.078790. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):483.

PMID:
29330218
4.

Molecular properties associated with transporter-mediated drug disposition.

Varma MV, Lai Y, El-Kattan AF.

Adv Drug Deliv Rev. 2017 Jul 1;116:92-99. doi: 10.1016/j.addr.2017.05.014. Epub 2017 May 26. Review.

PMID:
28554577
5.

Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters.

Varma MV, El-Kattan AF, Feng B, Steyn SJ, Maurer TS, Scott DO, Rodrigues AD, Tremaine LM.

Clin Pharmacol Ther. 2017 Jul;102(1):33-36. doi: 10.1002/cpt.595. Epub 2017 Feb 3. No abstract available.

PMID:
27984654
6.

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.

El-Kattan AF, Varma MV, Steyn SJ, Scott DO, Maurer TS, Bergman A.

Pharm Res. 2016 Dec;33(12):3021-3030. Epub 2016 Sep 12.

PMID:
27620173
7.

Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.

Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, Kalgutkar AS, El-Kattan AF, Rodrigues AD, Tremaine LM.

Clin Pharmacol Ther. 2017 Mar;101(3):406-415. doi: 10.1002/cpt.520. Epub 2016 Nov 18.

PMID:
27648490
9.

Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.

Varma MV, El-Kattan AF.

J Clin Pharmacol. 2016 Jul;56 Suppl 7:S99-S109. doi: 10.1002/jcph.695. Review.

PMID:
27385183
10.

Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Varma MV, Steyn SJ, Allerton C, El-Kattan AF.

Pharm Res. 2015 Dec;32(12):3785-802. doi: 10.1007/s11095-015-1749-4. Epub 2015 Jul 9.

PMID:
26155985
11.

Strategies for skeletal muscle targeting in drug discovery.

Ebner DC, Bialek P, El-Kattan AF, Ambler CM, Tu M.

Curr Pharm Des. 2015;21(10):1327-36. Review.

PMID:
25269560
12.

Intestinal targeting of drugs: rational design approaches and challenges.

Filipski KJ, Varma MV, El-Kattan AF, Ambler CM, Ruggeri RB, Goosen TC, Cameron KO.

Curr Top Med Chem. 2013;13(7):776-802. Review.

PMID:
23578023
13.

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.

Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, Lai Y.

Drug Metab Dispos. 2013 May;41(5):966-74. doi: 10.1124/dmd.112.050583. Epub 2013 Feb 7.

14.

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV.

Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):459-72. doi: 10.1517/17425255.2013.759210. Epub 2013 Jan 21. Review.

PMID:
23331046
15.

Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.

Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V.

Pharm Res. 2013 Apr;30(4):1188-99. doi: 10.1007/s11095-012-0956-5. Epub 2013 Jan 10.

PMID:
23307347
16.

Renal transporters in drug disposition, drug-drug interactions, and nephrotoxicity.

Feng B, El-Kattan AF, Radi ZA.

Curr Protoc Toxicol. 2012 Aug;Chapter 23:Unit 23.3.1-15. doi: 10.1002/0471140856.tx2303s53.

PMID:
22896010
17.

Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion.

Varma MV, Chang G, Lai Y, Feng B, El-Kattan AF, Litchfield J, Goosen TC.

Drug Metab Dispos. 2012 Aug;40(8):1527-37. doi: 10.1124/dmd.112.044628. Epub 2012 May 11.

18.

pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.

Varma MV, Gardner I, Steyn SJ, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KS, El-Kattan AF.

Mol Pharm. 2012 May 7;9(5):1199-212. doi: 10.1021/mp2004912. Epub 2012 Apr 26.

PMID:
22489626
19.

In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.

Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Jun;40(6):1085-92. doi: 10.1124/dmd.111.043489. Epub 2012 Mar 1. Review.

20.

Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes.

Kimoto E, Walsky R, Zhang H, Bi YA, Whalen KM, Yang YS, Linder C, Xiao Y, Iseki K, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Feb;40(2):407-11. doi: 10.1124/dmd.111.039297. Epub 2011 Oct 26.

21.

Development of a new permeability assay using low-efflux MDCKII cells.

Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD.

J Pharm Sci. 2011 Nov;100(11):4974-85. doi: 10.1002/jps.22674. Epub 2011 Jul 15.

PMID:
21766308
22.

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, Litchfield J, Goosen TC, El-Kattan AF.

Mol Pharm. 2011 Aug 1;8(4):1303-13. doi: 10.1021/mp200103h. Epub 2011 Jul 11.

PMID:
21710988
23.

Targeting intestinal transporters for optimizing oral drug absorption.

Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, El-Kattan AF.

Curr Drug Metab. 2010 Nov;11(9):730-42. Review.

PMID:
21189135
24.

Diethylation labeling combined with UPLC/MS/MS for simultaneous determination of a panel of monoamine neurotransmitters in rat prefrontal cortex microdialysates.

Ji C, Li W, Ren XD, El-Kattan AF, Kozak R, Fountain S, Lepsy C.

Anal Chem. 2008 Dec 1;80(23):9195-203. doi: 10.1021/ac801339z.

PMID:
19551941
25.
26.

Evaluation of derivatives of 3-(2-oxo-1-pyrrolidine)hexahydro-1H-azepine-2-one as dermal penetration enhancers: side chain length variation and molecular modeling.

Kim N, El-Kattan AF, Asbill CS, Kennette RJ, Sowell JW Sr, Latour R, Michniak BB.

J Control Release. 2001 Jun 15;73(2-3):183-96.

PMID:
11516496
27.

The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities.

El-Kattan AF, Asbill CS, Kim N, Michniak BB.

Int J Pharm. 2001 Mar 14;215(1-2):229-40.

PMID:
11250108
28.

Enhancement of transdermal drug delivery: chemical and physical approaches.

Asbill CS, El-Kattan AF, Michniak B.

Crit Rev Ther Drug Carrier Syst. 2000;17(6):621-58. Review.

PMID:
11204737
29.

Effect of formulation variables on the percutaneous permeation of ketoprofen from gel formulations.

El-Kattan AF, Asbill CS, Kim N, Michniak BB.

Drug Deliv. 2000 Jul-Sep;7(3):147-53.

PMID:
10989915
30.

Supplemental Content

Loading ...
Support Center